Abstract:IMPORTANCE This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC. DESIGN, SETTING, AND PARTICIPANTS This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020. INTERVENTIONS Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m(2), day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m(2), days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs >= 50%). MAIN OUTCOMES AND MEASURES The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC). Secondary end points included overall survival, investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), and IRC-assessed duration of response, as well as the incidence and severity of adverse events (AEs). RESULTS Overall, 355 patients (median [range] age, 62 [34-74] years; 330 men [91.7%]) with sq-NSCLC received treatment. After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone (arm C, 5.5 months; hazard ratios were 0.524 (95% CI, 0.370-0.742; P < .001 [A vs C]) and 0.478 (95% CI, 0.336-0.679; P < .001 [B vs C]). Higher IRC-assessed ORR and longer IRC-assessed duration of response were observed in arms A (72.5%; 8.2 months) and B (74.8%; 8.6 months) vs C (49.6%; 4.2 months). No association was observed between PD-L1 expression and IRC-assessed PFS or ORR. Discontinuation of any treatment because of AEs was reported in 15 (12.5%; arm A), 35 (29.7%; arm B), and 18 (15.4%; arm C) patients. In each arm, the most common grade of 3 or greater AE was decreased neutrophil levels, which aligned with known chemotherapy toxic effects. Six treatment-related AEs leading to death occurred; however, no deaths were solely attributed to tislelizumab. CONCLUSIONS AND RELEVANCE In this phase 3 randomized clinical trial, adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs, and a manageable safety/tolerability profile in patients with advanced sq-NSCLC, regardless of PD-L1 expression.

Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.

137P Tislelizumab Combined with Chemotherapy As Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially Resectable Squamous Non-Small-cell Lung Cancer (TACT)

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Camrelizumab combined with TIP (paclitaxel+cisplatin+ifosfamide) as neoadjuvant treatment of locally advanced penile cancer before lymphadenectomy: An exploratory, phase II study.

Anti-EGFR Antibody Plus Anti-Pd-1 Antibody and Chemotherapy As a Neoadjuvant Regimen for Patients with Locally-Advanced Penile Squamous Cell Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial.

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma.

Neoadjuvant Docetaxel, Cisplatin and Ifosfamide (ITP) Combination Chemotherapy for Treating Penile Squamous Cell Carcinoma Patients with Terminal Lymph Node Metastasis

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

First‐line PD‐1 Inhibitor & EGFR Blockade & Platinum‐based Chemotherapy (PEP) for Stage IV Penile Cancer

First-line Programmed Death Receptor-1 (PD-1) Inhibitor and Epidermal Growth Factor Receptor (EGFR) Blockade, Combined with Platinum-Based Chemotherapy, for Stage IV Penile Cancer.

Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter Study

1264P Updated Analysis of Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report

PD-1 inhibitor combined with paclitaxel and cisplatin in the treatment of recurrent and metastatic hypopharyngeal/laryngeal squamous cell carcinoma: efficacy and survival outcomes

[Efficacy and Safety of Neoadjuvant Toripalimab Combined with Nimotuzumab and Chemotherapy in Patients with Unresectable Stage Ⅳ Squamous Cell Carcinoma of Penis].

P1.04-36 Tislelizumab Combined with Chemotherapy As First-Line Treatment in Chinese Patients with Advanced Lung Cancer

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).